Display Settings:


Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Curr Opin Immunol. 1998 Oct;10(5):573-80.

Clinical applications of TNF-alpha in cancer.

Author information

  • 1Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier UniversitaireVaudois (CHUV), Rue du Bugnon 46, CH-1011, Lausanne, Switzerland. Ferdy.Lejeune@chuv.hospvd.ch


High-dose TNF-alpha plus chemotherapy, with or without IFN-gamma, can be safely administered regionally through isolated limb perfusion. This procedure produced between 70% and 80% complete remission in cases of in transit melanoma metastases and between 25% and 36% complete remission in cases of inextirpable soft-tissue sarcomas. Dual targeting is involved; TNF-alpha and IFN-gamma induce apoptosis of angiogenic endothelium, while melphalan induces apoptosis of tumour cells.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk